Abera Bioscience AB Logo

Abera Bioscience AB

ABERA | SPGR

Overview

Corporate Details

ISIN(s):
SE0015245097
LEI:
549300IO3Q8IE2FDUS29
Country:
Sweden
Address:
BOX 1747, 751 47 Uppsala
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Abera Bioscience AB is a biotechnology company developing next-generation mucosal vaccines based on its proprietary vaccine delivery platform, BERA. This novel platform utilizes Outer Membrane Vesicles (OMVs) that can be decorated with large amounts of one or more antigens, enabling the creation of efficient multivalent vaccines that elicit a strong and broad protective immune response. Abera's pipeline focuses on vaccine candidates for mucosal administration, such as nasal sprays, to address significant infectious disease challenges. The company's lead candidate is a universal pneumococcal vaccine (Ab-01.12) advancing towards clinical trials. Additionally, Abera is active in pandemic preparedness, developing technologies like a nasal influenza vaccine candidate.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Abera Bioscience AB. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Abera Bioscience AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Abera Bioscience AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Genmab Logo
Develops antibody therapeutics for cancer and serious diseases using proprietary technology.
Denmark GMAB
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
genOway Logo
Develops genetically engineered preclinical models for biopharma and academic research.
France ALGEN
GenSight Biologics S.A. Logo
Biopharma developing gene therapies for retinal neurodegenerative diseases and CNS disorders.
France SIGHT
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Guard Therapeutics International AB Logo
Clinical-stage biotech developing protein-based therapies for acute kidney injury.
Sweden GUARD
Gubra A/S Logo
Preclinical CRO and peptide drug developer for metabolic and fibrotic diseases.
Denmark GUBRA
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops novel therapies for life-threatening blood disorders, cancers, and autoimmune diseases.
United Kingdom HEMO
Herantis Pharma Oyj Logo
Clinical-stage biotech developing therapies for neurodegenerative disorders like Parkinson's.
Finland HRTIS